Clinical Trial Update: Dose-finding, Safety and Efficacy Study of Radium-223 Dichloride (XOFIGO) in RCC Patients With Bone Metastases. (EIFFEL) [Phase 1, Phase 2]

View source ↗

Summary

This document describes an early-phase dose-finding and safety/efficacy study of radium-223 dichloride (Xofigo) in patients with clear-cell renal cell carcinoma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma
• Renal Cell Carcinoma

Drugs mentioned

• Xofigo (radium-223 dichloride)

Snippet

Sponsor: Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie | Conditions: Clear-cell Metastatic Renal Cell Carcinoma, Bone Metastases | Phase 1, Phase 2 | Status: UNKNOWN